Trial Profile
A Two-Stage Randomized Placebo-Controlled Ascending Dose Phase I/ IIa Study to Evaluate Safety, Tolerability, Pharmacodynamic Effects and Preliminary Efficacy of an Anti-Interleukin 1 Beta Vaccine (CYT 013 IL1bQb) in Patients With Type 2 Diabetes Mellitus.
Status:
Suspended
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs CYT 013 Il1bQb (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 18 Jun 2013 Results presented at the 95th Annual Meeting of the Endocrine Society.
- 10 Feb 2012 Actual patient number (48) added as reported by ClinicalTrials.gov.